78 related articles for article (PubMed ID: 3589706)
41. [Weekly CHOP chemotherapy in the treatment of intermediate-grade non-Hodgkin's lymphomas--cooperative group study by seven institutes].
Kobayashi M; Sao H; Mizuta S; Kamiya O; Ohara K; Nagata K; Takeyama H; Watanabe E; Yamada H; Mizuno H
Rinsho Ketsueki; 1990 Oct; 31(10):1656-63. PubMed ID: 2255056
[TBL] [Abstract][Full Text] [Related]
42. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
43. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
[TBL] [Abstract][Full Text] [Related]
44. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
45. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
Cabanillas F; Velasquez WS; McLaughlin P; Jagannath S; Hagemeister FB; Redman JR; Swan F; Rodriguez MA
Semin Hematol; 1988 Apr; 25(2 Suppl 2):47-50. PubMed ID: 3041599
[TBL] [Abstract][Full Text] [Related]
46. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
[TBL] [Abstract][Full Text] [Related]
47. The present status of therapy for patients with aggressive non-Hodgkin's lymphoma.
Vose JM; Armitage JO
Ann Oncol; 1991 Feb; 2 Suppl 2():171-6. PubMed ID: 2049315
[TBL] [Abstract][Full Text] [Related]
48. Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin's lymphomas and acute leukemias.
Zurborn KH; Gram J; Glander K; Delbrück K; Pelzer H; Löffler H; Bruhn HD
Eur J Haematol; 1991 Jul; 47(1):55-9. PubMed ID: 1714407
[TBL] [Abstract][Full Text] [Related]
49. Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors.
Armand JP; Ribrag V; Harrousseau JL; Abrey L
Ther Clin Risk Manag; 2007 Jun; 3(2):213-24. PubMed ID: 18360630
[TBL] [Abstract][Full Text] [Related]
50. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project.
Cancer; 1982 May; 49(10):2112-35. PubMed ID: 6896167
[TBL] [Abstract][Full Text] [Related]
51. Management of histologically aggressive non-Hodgkin's lymphomas.
Linch DC
Br J Haematol; 1994 Apr; 86(4):691-4. PubMed ID: 7918060
[No Abstract] [Full Text] [Related]
52. European experience with ifosfamide in lymphomas.
von Kalle AK; Schaadt M; Diehl V
Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
[TBL] [Abstract][Full Text] [Related]
53. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
Fisher RI; Longo DL; DeVita VT; Hubbard SM; Miller TP; Young RC
Ann Oncol; 1991 Jan; 2 Suppl 1():33-5. PubMed ID: 1710487
[TBL] [Abstract][Full Text] [Related]
54. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
55. Practical approaches to the management of aggressive lymphomas in the community practice.
Winokur SH
Semin Hematol; 1987 Apr; 24(2 Suppl 1):41-4. PubMed ID: 3589706
[TBL] [Abstract][Full Text] [Related]
56. Advances in chemotherapy for large cell lymphoma.
Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
[TBL] [Abstract][Full Text] [Related]
57. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
